A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
Clinical trial NCT05049798 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05049798
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2021-08-25
- Primary completion
- 2027-08-01
- Enrollment
- 1314
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.